CN101433641A - 一种口服中药组合物及其制备、服用、质量检查方法和用途 - Google Patents
一种口服中药组合物及其制备、服用、质量检查方法和用途 Download PDFInfo
- Publication number
- CN101433641A CN101433641A CNA2008100465465A CN200810046546A CN101433641A CN 101433641 A CN101433641 A CN 101433641A CN A2008100465465 A CNA2008100465465 A CN A2008100465465A CN 200810046546 A CN200810046546 A CN 200810046546A CN 101433641 A CN101433641 A CN 101433641A
- Authority
- CN
- China
- Prior art keywords
- solution
- preparation
- chinese medicine
- parts
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 144
- 239000003814 drug Substances 0.000 claims abstract description 119
- 241001465754 Metazoa Species 0.000 claims abstract description 40
- 210000000232 gallbladder Anatomy 0.000 claims abstract description 29
- 210000000941 bile Anatomy 0.000 claims abstract description 21
- 201000001883 cholelithiasis Diseases 0.000 claims abstract description 19
- 230000001737 promoting effect Effects 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 210000004185 liver Anatomy 0.000 claims abstract description 13
- 208000004880 Polyuria Diseases 0.000 claims abstract description 10
- 230000035619 diuresis Effects 0.000 claims abstract description 10
- 208000002193 Pain Diseases 0.000 claims abstract description 8
- 210000001015 abdomen Anatomy 0.000 claims abstract description 8
- 230000036407 pain Effects 0.000 claims abstract description 8
- 208000022531 anorexia Diseases 0.000 claims abstract description 6
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 6
- 206010023126 Jaundice Diseases 0.000 claims abstract description 5
- 208000006750 hematuria Diseases 0.000 claims abstract description 5
- 230000028327 secretion Effects 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 213
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 195
- 238000012360 testing method Methods 0.000 claims description 167
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 111
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 108
- 239000013558 reference substance Substances 0.000 claims description 95
- 239000007788 liquid Substances 0.000 claims description 93
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 72
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 64
- 239000000463 material Substances 0.000 claims description 63
- 239000003208 petroleum Substances 0.000 claims description 58
- 239000000047 product Substances 0.000 claims description 57
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 54
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 53
- 239000000741 silica gel Substances 0.000 claims description 48
- 229910002027 silica gel Inorganic materials 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 41
- 238000000605 extraction Methods 0.000 claims description 40
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 37
- 239000000853 adhesive Substances 0.000 claims description 37
- 230000001070 adhesive effect Effects 0.000 claims description 37
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 37
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 37
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 37
- 239000007921 spray Substances 0.000 claims description 35
- 229960000583 acetic acid Drugs 0.000 claims description 33
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 31
- 239000004380 Cholic acid Substances 0.000 claims description 31
- 235000019416 cholic acid Nutrition 0.000 claims description 31
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 31
- 229960002471 cholic acid Drugs 0.000 claims description 31
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 30
- 239000012362 glacial acetic acid Substances 0.000 claims description 30
- 238000010992 reflux Methods 0.000 claims description 29
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 claims description 24
- 239000012567 medical material Substances 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims description 18
- 238000002835 absorbance Methods 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- 230000003760 hair shine Effects 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 11
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 11
- 235000012141 vanillin Nutrition 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 7
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 6
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 6
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims description 6
- 241000282898 Sus scrofa Species 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims description 6
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 6
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 6
- 229940025878 hesperidin Drugs 0.000 claims description 6
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims description 6
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- QLRGSUBBRSJVLL-UHFFFAOYSA-N benzene;chloroform;methanol Chemical compound OC.ClC(Cl)Cl.C1=CC=CC=C1 QLRGSUBBRSJVLL-UHFFFAOYSA-N 0.000 claims description 5
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 5
- 241000612166 Lysimachia Species 0.000 claims description 4
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000004575 stone Substances 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 241001523579 Ostrea Species 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 3
- 230000036592 analgesia Effects 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 2
- 238000003808 methanol extraction Methods 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 208000009911 Urinary Calculi Diseases 0.000 abstract description 2
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 206010000087 Abdominal pain upper Diseases 0.000 abstract 1
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 206010007027 Calculus urinary Diseases 0.000 abstract 1
- 241000522190 Desmodium Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000015924 Lithiasis Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 314
- 229940079593 drug Drugs 0.000 description 54
- 239000000706 filtrate Substances 0.000 description 51
- 239000000284 extract Substances 0.000 description 32
- 238000004809 thin layer chromatography Methods 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 230000008569 process Effects 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000001802 infusion Methods 0.000 description 11
- 241000283898 Ovis Species 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 9
- 239000006187 pill Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- 208000000913 Kidney Calculi Diseases 0.000 description 6
- 206010029148 Nephrolithiasis Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 6
- 238000006297 dehydration reaction Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000001117 sulphuric acid Substances 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- 238000011003 system suitability test Methods 0.000 description 6
- 208000031868 Calculus ureteric Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 241000282894 Sus scrofa domesticus Species 0.000 description 5
- 208000000014 Ureteral Calculi Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000003518 caustics Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003809 bile pigment Substances 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010004637 Bile duct stone Diseases 0.000 description 2
- 201000009331 Choledocholithiasis Diseases 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005242 forging Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282443 Ursidae Species 0.000 description 1
- 241000282453 Ursus americanus Species 0.000 description 1
- 241000282454 Ursus arctos Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100465465A CN101433641B (zh) | 2008-11-13 | 2008-11-13 | 一种口服中药组合物及其制备、服用、质量检查方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100465465A CN101433641B (zh) | 2008-11-13 | 2008-11-13 | 一种口服中药组合物及其制备、服用、质量检查方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101433641A true CN101433641A (zh) | 2009-05-20 |
CN101433641B CN101433641B (zh) | 2012-06-27 |
Family
ID=40708381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100465465A Active CN101433641B (zh) | 2008-11-13 | 2008-11-13 | 一种口服中药组合物及其制备、服用、质量检查方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101433641B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716308A (zh) * | 2012-06-28 | 2012-10-10 | 陈慧婷 | 治疗鼓胀的茵陈蒿中药制剂及制备方法 |
CN103110763A (zh) * | 2013-01-31 | 2013-05-22 | 陈欣 | 一种治疗泌尿性结石的中药组合物及其制备方法 |
CN103977150A (zh) * | 2014-06-02 | 2014-08-13 | 张清敏 | 一种治疗病毒性肝炎的中药制剂及制备方法 |
CN104524458A (zh) * | 2014-12-24 | 2015-04-22 | 赵红 | 一种治疗肝胆结石的中药散剂及其制备方法 |
CN110946761A (zh) * | 2019-12-17 | 2020-04-03 | 东阿阿胶股份有限公司 | 一种猪苓汤基准物质的制备方法和定性检测方法 |
CN110967440A (zh) * | 2018-09-28 | 2020-04-07 | 九芝堂股份有限公司 | 一种鉴别阿珍养血口服液中地肤子的方法 |
CN114272291A (zh) * | 2020-09-28 | 2022-04-05 | 谭军 | 一种用于各种身体结石的超强化石配方 |
CN114441703A (zh) * | 2021-12-30 | 2022-05-06 | 贵州威利德制药有限公司 | 一种和肝利胆糖浆的检测方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100428950C (zh) * | 2006-07-05 | 2008-10-29 | 河北农业大学 | 一种防治鸡肾肿病的药物 |
-
2008
- 2008-11-13 CN CN2008100465465A patent/CN101433641B/zh active Active
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716308A (zh) * | 2012-06-28 | 2012-10-10 | 陈慧婷 | 治疗鼓胀的茵陈蒿中药制剂及制备方法 |
CN102716308B (zh) * | 2012-06-28 | 2014-02-26 | 陈慧婷 | 治疗鼓胀的茵陈蒿中药制剂及制备方法 |
CN103110763A (zh) * | 2013-01-31 | 2013-05-22 | 陈欣 | 一种治疗泌尿性结石的中药组合物及其制备方法 |
CN103110763B (zh) * | 2013-01-31 | 2014-08-20 | 李博 | 一种治疗泌尿性结石的中药组合物及其制备方法 |
CN103977150A (zh) * | 2014-06-02 | 2014-08-13 | 张清敏 | 一种治疗病毒性肝炎的中药制剂及制备方法 |
CN104524458A (zh) * | 2014-12-24 | 2015-04-22 | 赵红 | 一种治疗肝胆结石的中药散剂及其制备方法 |
CN110967440A (zh) * | 2018-09-28 | 2020-04-07 | 九芝堂股份有限公司 | 一种鉴别阿珍养血口服液中地肤子的方法 |
CN110946761A (zh) * | 2019-12-17 | 2020-04-03 | 东阿阿胶股份有限公司 | 一种猪苓汤基准物质的制备方法和定性检测方法 |
CN114272291A (zh) * | 2020-09-28 | 2022-04-05 | 谭军 | 一种用于各种身体结石的超强化石配方 |
CN114441703A (zh) * | 2021-12-30 | 2022-05-06 | 贵州威利德制药有限公司 | 一种和肝利胆糖浆的检测方法 |
CN114441703B (zh) * | 2021-12-30 | 2023-12-15 | 贵州威利德制药有限公司 | 一种和肝利胆糖浆的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101433641B (zh) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101433641B (zh) | 一种口服中药组合物及其制备、服用、质量检查方法和用途 | |
CN100348248C (zh) | 一种治疗痛风的中药组合物及制备方法 | |
CN107997176A (zh) | 一种防治小儿积食厌食的健胃消食保健食品 | |
CN103028065B (zh) | 一种紫香益母制剂及其制备方法和检测方法 | |
CN102526427B (zh) | 治疗胃肠疾病的中药组合物及质量检测方法 | |
CN102188494B (zh) | 一种治疗猪高热病的中药药物 | |
CN100386093C (zh) | 一种治疗感冒及上呼吸道感染的药物组合物、其制备方法及其用途 | |
CN103356630B (zh) | 含有己酮可可碱和普卡必利的药物组合物及其医药用途 | |
CN106389717A (zh) | 一种用于治疗仔猪耐药性大肠杆菌病的中药组合物 | |
CN109464583A (zh) | 一种兽用抗炎中药组合物及其制备方法和应用 | |
CN110384787A (zh) | 一种治疗过敏性鼻炎的中药组合物及其制备方法 | |
CN101485779B (zh) | 一种治疗银屑病的药物组合物及制备方法和质量检测方法 | |
CN100574781C (zh) | 一种治疗痛风的兽药及其制备方法和用途 | |
CN101406556B (zh) | 一种用于治疗急性前列腺炎、前列腺增生的中药制剂及其制备方法 | |
CN102274433A (zh) | 一种治疗慢性盆腔炎的中药及其制备方法 | |
CN100428925C (zh) | 一种香薷提取物的制剂、质量控制方法 | |
CN104784621A (zh) | 一种治疗腹泻的中药组合物及其制备方法和应用 | |
CN104189346A (zh) | 一种新型促胃肠动力的药物组合物及其制备方法 | |
CN108704036A (zh) | 一种治疗痛风的复方中药制剂及其制备方法 | |
CN103520661A (zh) | 一种治疗直肠炎、结肠炎、肠易激综合症的中药肠溶片及其制备方法与应用 | |
CN102961426B (zh) | 一种千喜胶囊及其制备方法 | |
CN103463402B (zh) | 小儿哮喘用中药组合物及其制备方法 | |
CN103520638B (zh) | 一种治疗前列腺肥大症的中药复方组合物及其制备方法及其应用 | |
CN114767810B (zh) | 一种治疗急性肺损伤的中药组合物及制备方法和应用 | |
CN102861302B (zh) | 一种治疗前列腺增生的中药制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN SUNNYHOPE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGHUI PHARMACEUTICAL CO., LTD., CHENGDU CITY Effective date: 20120203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610036 CHENGDU, SICHUAN PROVINCE TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120203 Address after: No. 3 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610041 Applicant after: Sichuan Sunnyhope Pharmaceutical Co., Ltd. Address before: 610036 No. 30 Shu West Road, Sichuan, Chengdu Applicant before: Zhonghui Pharmaceutical Co., Ltd., Chengdu City |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oral Chinese medicinal composition as well as preparing, taking and quality inspecting methods and use thereof Effective date of registration: 20141120 Granted publication date: 20120627 Pledgee: China Huarong Asset Management Limited by Share Ltd Sichuan branch Pledgor: Sichuan Sunnyhope Pharmaceutical Co., Ltd. Registration number: 2014510000035 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180209 Granted publication date: 20120627 Pledgee: China Huarong Asset Management Limited by Share Ltd Sichuan branch Pledgor: Sichuan Sunnyhope Pharmaceutical Co., Ltd. Registration number: 2014510000035 |